Factors associated with complicated buprenorphine inductions
- PMID: 20682186
- PMCID: PMC4755478
- DOI: 10.1016/j.jsat.2010.04.001
Factors associated with complicated buprenorphine inductions
Abstract
Despite data supporting its efficacy, barriers to implementation of buprenorphine for office-based treatment are present. Complications can occur during buprenorphine inductions, yet few published studies have examined this phase of treatment. To examine factors associated with complications during buprenorphine induction, we conducted a retrospective chart review of the first 107 patients receiving buprenorphine treatment in an urban community health center. The primary outcome, defined as complicated induction (precipitated or protracted withdrawal), was observed in 18 (16.8%) patients. Complicated inductions were associated with poorer treatment retention (than routine inductions) and decreased over time. Factors independently associated with complicated inductions included recent use of prescribed methadone, recent benzodiazepine use, no prior experience with buprenorphine, and a low initial dose of buprenorphine/naloxone. Findings from this study and further investigation of patient characteristics and treatment characteristics associated with complicated inductions can help guide buprenorphine treatment strategies.
Copyright 2010 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest: Dr. Whitley has served as a speaker for Reckitt Benckiser. All other authors have no conflict of interest.
Similar articles
-
Less pain, more gain: buprenorphine-naloxone and patient retention in treatment.J Addict Dis. 2006;25(3):97-104. doi: 10.1300/J069v25n03_12. J Addict Dis. 2006. PMID: 16956874
-
Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.Am J Addict. 2004;13 Suppl 1(Suppl 1):S42-66. doi: 10.1080/10550490490440807. Am J Addict. 2004. PMID: 15204675 Free PMC article.
-
Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.Clin Drug Investig. 2010;30 Suppl 1:21-6. doi: 10.2165/11536010-000000000-00000. Clin Drug Investig. 2010. PMID: 20450242
-
Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.Drugs. 2009;69(5):577-607. doi: 10.2165/00003495-200969050-00006. Drugs. 2009. PMID: 19368419 Review.
-
Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?Can Fam Physician. 2017 Mar;63(3):200-205. Can Fam Physician. 2017. PMID: 28292795 Free PMC article. Review.
Cited by
-
Prior Experience with Non-Prescribed Buprenorphine: Role in Treatment Entry and Retention.J Subst Abuse Treat. 2015 Oct;57:57-62. doi: 10.1016/j.jsat.2015.04.010. Epub 2015 May 7. J Subst Abuse Treat. 2015. PMID: 25980599 Free PMC article.
-
Methadone and neonatal abstinence syndrome (NAS): what we think we know, but do not.Front Pediatr. 2023 Dec 21;11:1316583. doi: 10.3389/fped.2023.1316583. eCollection 2023. Front Pediatr. 2023. PMID: 38188918 Free PMC article. Review.
-
Case Series: Limited Opioid Withdrawal With Use of Transdermal Buprenorphine to Bridge to Sublingual Buprenorphine in Hospitalized Patients.Am J Addict. 2020 Jan;29(1):73-76. doi: 10.1111/ajad.12964. Epub 2019 Oct 18. Am J Addict. 2020. PMID: 31626394 Free PMC article.
-
Patient experiences of buprenorphine dispensing from a mobile medical unit.Addict Sci Clin Pract. 2024 Jul 18;19(1):53. doi: 10.1186/s13722-024-00484-4. Addict Sci Clin Pract. 2024. PMID: 39026326 Free PMC article.
-
Factors that distinguish opioid withdrawal during induction with buprenorphine microdosing: a configurational analysis.Addict Sci Clin Pract. 2022 Oct 4;17(1):55. doi: 10.1186/s13722-022-00336-z. Addict Sci Clin Pract. 2022. PMID: 36195895 Free PMC article.
References
-
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. fourth, text revision. Washington, DC: 2000.
-
- Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction Treatment improvement protocol (TIP) series 40. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004. - PubMed
-
- Fiellin DA. The first three years of buprenorphine in the United States: Experience to date and future directions. Journal of Addiction Medicine. 2007;1:62–67. - PubMed
-
- Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. Journal of Addictive Diseases. 2006;25:91–103. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical